DEA Okays Bulk Pot Production for Researchers: Objections Invited
Published Date: 1/23/2026
Notice
Summary
Maridose LLC wants to become a big-time maker of marijuana and related substances to help researchers study them. People already registered or interested can share their thoughts or ask for a hearing by March 24, 2026. This move could speed up research but doesn’t change any other drug rules or costs right now.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New Supplier for DEA Research Cannabis
On January 1, 2026, Maridose LLC applied to be a DEA-registered bulk manufacturer of marihuana (code 7360), marihuana extract (code 7350), and tetrahydrocannabinols (code 7370), all Schedule I substances. If registered, the company would be allowed to manufacture these substances in bulk to supply Drug Enforcement Administration–registered researchers for their approval studies; no other activities for these drug codes would be authorized. Comments or requests for a hearing must be submitted by March 24, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-01297, Application for Authorization To Export Electric Energy; Electric Power Markets USA, LLC
Electric Power Markets USA, LLC wants permission to send electricity from the U.S. to Mexico for the next five years. This affects energy buyers and sellers in Texas and could boost cross-border power trade without hurting U.S. electricity supplies. If you have thoughts or concerns, you’ve got until February 23, 2026, to speak up!
Next: 2026-01305, Bulk Manufacturer of Controlled Substances Application: Organic Consultants LLC DBA Cascade Chemistry
Organic Consultants LLC, also known as Cascade Chemistry, wants to become a big-time maker of certain controlled drugs like codeine and oxycodone. They plan to produce small amounts mainly for testing and research. If you have thoughts or objections, you’ve got until March 24, 2026, to speak up online—no cost involved!